Book a Meeting
Creative Biolabs - ADCC+ Antibody

Anti-Embigin Antibody, Non-Fucosylated (7C4E10) (CAT#: BioBet-813ZP) Datasheet

Target
Embigin
Isotype
IgG2b
Description
ADCC-Enhanced anti-Embigin (7C4E10) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Autoimmune Diseases
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Embigin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
EMB
Full Name
embigin
Background
This gene encodes a transmembrane glycoprotein that is a member of the immunoglobulin superfamily. The encoded protein may be involved in cell growth and development by mediating interactions between the cell and extracellular matrix. A pseudogene of this gene is found on chromosome 1.
Alternative Names
EMB; embigin; GP70; embigin homolog
Gene ID
133418
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with EMB include Splenic Manifestation Of Leukemia and Conidiobolomycosis.
Related Pathways
Its related pathways are Autophagy Pathway and MAPK Erk Pathway.
Function
It plays a role in the growth of motor neurons and the formation of neuromuscular connections. After muscle denervation, it promotes the sprouting of nerve endings and the formation of additional acetylcholine receptor clusters at synapses, without affecting the number or morphology of Schwann cells. After the denervated endplates are neuralized, the contraction of the terminal buds is delayed. It may act on the target cell membrane of the monocarboxylic acid transporters SLC16A1 and SLC16A7 (similarity).
Post-translational modifications
1.Glycosylation at Asn54, Asn61, Asn75, Asn85, Asn100, Asn189, Asn196, Asn213, and Asn218 2.Modification sites at PhosphoSitePlus 3.Ubiquitination at Lys135 and Lys223
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2b
Antibody Clone
7C4E10
Host
Rat
Species Reactivity
Human
Description
This is an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent the prophylaxis or therapy of autoimmune diseases or allergic diseases.
Antibody Indication
Autoimmune Diseases

Autoimmune Diseases

Related Products

Anti-Embigin Antibody, Non-Fucosylated (3E64D1) (CAT#: BioBet-814ZP)
Anti-Embigin Antibody, Non-Fucosylated (3E64) (CAT#: BioBet-810ZP)
Anti-Embigin Antibody, Non-Fucosylated (6G1E6) (CAT#: BioBet-812ZP)
Anti-Embigin Antibody, Non-Fucosylated (2G21) (CAT#: BioBet-811ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *

ISO 9001 Certified - Creative Biolabs Quality Management System.
© 2025 Creative Biolabs. All rights reserved.
Merry Christmas Merry Christmas